[{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Oxford Biomedica"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Announces that Sio Gene Therapies Intends to Cease the License Agreement for Gene Therapy Programme in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Oxford Biomedica"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AviadoBio Announces Initiation of Phase 1\/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"AviadoBio"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"AviadoBio"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain, enabling distribution to brain areas affected by FTD while limiting systemic exposure.
AVB-101 is an investigational gene therapy designed to halt disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels in the brain for the treatment of frontotemporal dementia.
Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease. Sio is currently conducting a Phase 2 SUNRISE-PD trial with AXO-Lenti-PD.
Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinson’s Disease based on Oxford Biomedica’s LentiVector® platform.